For the modern retina specialist, the management of age-related macular degeneration (AMD) has evolved from simple observation to a high-resolution analysis of the photoreceptor–retinal pigment epithelium (RPE)–choroid unit. Bridging the gap between ex vivo histology and in vivo multimodal imaging is essential for identifying biomarkers that guide prognosis and emerging therapeutic strategies.
The Inner Retina: Beyond the Outer Layers
While AMD is traditionally viewed as an outer retinal disease, structural OCT and histological evidence now confirm significant inner retinal neurodegeneration. Studies show that ganglion cell complex (GCC) thinning begins as early as the intermediate stages of AMD. This may be driven by transneuronal degeneration or mitochondrial dysfunction. Furthermore, Müller cells undergo drastic remodeling, creating complex subretinal glial membranes in areas of geographic atrophy (GA). These membranes may act as physical barriers to future subretinal stem cell replacement therapies.
Photoreceptor Vulnerability and the Role of Rods
Histology has long highlighted that rod photoreceptors are more vulnerable than cones in early AMD, particularly in the parafovea. This loss often manifests clinically as delayed rod-mediated dark adaptation (RMDA), which is a sensitive functional biomarker for disease progression. Subretinal drusenoid deposits (SDD), or reticular pseudodrusen, represent a distinct phenotypic manifestation of dysregulated lipid cycling above the RPE. On OCT, these lesions correlate with a progressive decline in photoreceptor integrity and are a major risk factor for both GA and type 3 macular neovascularization (MNV).
Vascular Landscapes: Retinal and Choroidal Shifts
Advanced OCT Angiography (OCTA) has revolutionized our visualization of the choriocapillaris (CC). CC signal voids (flow deficits) are now recognized as early biomarkers that predict drusen enlargement and the expansion of GA lesions. Interestingly, retinal microvascular impairment may also precede neuronal loss, suggesting that parafoveal perfusion deficits could serve as an early marker of disease progression. In late-stage GA, we observe not only CC dropout but also progressive longitudinal constriction of the larger outer choroidal vessels.
The Neovascular Spectrum and Diagnostic Biomarkers
The classification of MNV has been refined through clinicopathologic correlation:
- Type 1 and 2 MNV originate from the choroid, often appearing on OCT as the “double layer sign” (DLS).
- Type 3 MNV (formerly RAP) originates from the deep retinal vascular plexus and extends downward toward the RPE.
- Non-exudative (Quiescent) MNV may actually provide a protective effect, acting as a surrogate for the damaged choriocapillaris and slowing the progression of RPE atrophy.
Consensus-based OCT terms like cRORA (complete RPE and outer retinal atrophy) and iRORA (incomplete) now provide a standardized framework for tracking RPE loss. Additionally, outer retinal tubulations (ORTs), which are hyperreflective tubular structures on OCT, represent a final stage of cone degeneration and remodeling in response to RPE disruption.
Conclusion
Understanding the tissue-level pathology behind the pixels on our screens allows for more precise clinical decision-making. As we move toward era-defining treatments for GA and personalized anti-VEGF protocols, the integration of histological insights with High-Res OCT and OCTA will remain the cornerstone of retina specialty practice.
Reference:
https://doi.org/10.1016/j.preteyeres.2026.101475
